Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90089


This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV melanoma.

Study summary:

In the Phase I/II trial, patients with resected stages III and IV melanoma who have been rendered free of disease, but are at high risk of relapse, are treated with peptides/IFA at a dose of 0.5 mg each peptide plus CTLA-4 antibody given intravenously, 3 mg/kg, after each vaccination. In the Phase II randomized study, patients are treated with the melanoma peptide vaccine alone, with CTLA-4 antibody, or with CTLA-4 antibody combined with IL-12 at 30 ng/kg with alum. The peptides are tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35 (27L) which are emulsified with IFA. The dosing schedule for both trials are at 1, 2, 3, 4, 5, and 6 months; then at 9 and 12 for a total of 8 vaccinations.


Inclusion criteria: - Diagnosis of stage III or IV cutaneous, mucosal, or ocular melanoma - Completely resected disease or disease-free - HLA-A2.1 positive - Tumor tissue available for immunohistochemical analysis and staining positive for at least 1 of the specified antigens - At least 1 month since prior therapy for cancer, including radiotherapy and adjuvant therapy - WBC count at least 3,000/mm3 - Granulocyte count at least 1,500/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin at least 9.0 gm/dL - Creatinine no greater than 2.0 mg/dL - Bilirubin no greater than 2.0 mg/dL - SGOT/SGPT no greater than 2.5 times upper limit of normal - ECOG performance status 0-1 - Have failed alpha-interferons (patients with resected stage III disease) Exclusion criteria: - Prior treatment with tyrosinase: 368-376(370D), gp100:209-217(210M), and MART-1:26-35(27L) peptides - Steroid therapy or other immunosuppressive medication requirement - Major systemic infections (e.g., pneumonia or sepsis) - Coagulation or bleeding disorders - Major medical illnesses of the gastrointestinal, cardiovascular, or respiratory systems - Allergic reaction to Montanide ISA 51 (incomplete Freund's adjuvant) - History of uveitis or autoimmune inflammatory eye disease - Other active autoimmune disease - Positive for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody - Pregnant or nursing



Primary Contact:

Principal Investigator
Jeffrey S. Weber, M.D., Ph.D.
University of Southern California/Norris Cancer Center

Backup Contact:


Location Contact:

Los Angeles, California 90089
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.